Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 30 versus ADZENYS XR ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 30 versus ADZENYS XR ODT.
ADDERALL 30 vs ADZENYS XR-ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Adzenys XR-ODT contains amphetamine, a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Initial: 9.4 mg orally once daily in the morning; titrate in increments of 9.4 mg per week based on tolerability and response. Maximum: 56.4 mg once daily.
None Documented
None Documented
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Approximately 9-14 hours in adults, 8-11 hours in children (6-12 years). Extended-release pharmacokinetics produce a longer clinical duration compared to immediate-release formulations.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Renal: approximately 90% as unchanged drug and metabolites (30%-40% as amphetamine, 40%-50% as hippuric acid and benzoic acid). Fecal: <4%. Biliary: negligible.
Category C
Category C
CNS Stimulant
CNS Stimulant